Jadhav V H, Patki A H, Mehta J M
Dr Bandorawalla Leprosy Hospital, Kondhawa, Pune.
Indian J Lepr. 1992 Oct-Dec;64(4):501-4.
One of the technical problems relating to the multidrug therapy of leprosy is the slow decrease in the bacteriological index (BI) in multibacillary patients. In this study we have compared a regimen containing rifampicin given daily for 9 months with the standard WHO multidrug regimen for multibacillary leprosy. We have found, at the end of two years, a significantly greater fall of BI in patients who had received the regimen containing daily rifampicin as compared to those who had received pulsed doses of rifampicin. The doses of dapsone and clofazimine were similar in these two groups. It appears that daily administration of rifampicin may be useful in treating multibacillary patients in whom reduction in the BI is slower than expected. However, in view of its high cost and the very much increased incidence of type-2 lepra reactions and hepatitis, daily rifampicin therapy cannot be recommended for a control programme.
与麻风病多药治疗相关的技术问题之一是多菌型患者细菌学指数（BI）下降缓慢。在本研究中，我们将每日服用利福平9个月的治疗方案与世界卫生组织多菌型麻风病标准多药治疗方案进行了比较。我们发现，在两年结束时，与接受脉冲剂量利福平的患者相比，接受每日利福平治疗方案的患者的BI下降幅度明显更大。这两组中氨苯砜和氯法齐明的剂量相似。每日服用利福平似乎对治疗细菌学指数下降比预期缓慢的多菌型患者有用。然而，鉴于其成本高昂以及2型麻风反应和肝炎的发病率大幅增加，每日利福平治疗不能推荐用于控制项目。
Zotero 插件